DRG Market Assessment reports

Since 2018, the U.S. treatment landscape for migraine prophylaxis has undergone a major expansion with the entry of the novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

With only a small percentage of patients harboring a biomarker-driven metastatic squamous non-small-cell lung cancer (NSCLC) (about 10% of all patients in the G7 countries), the preferred first-…

Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Such mutations lead…

Clarivate Epidemiology’s coverage of the human papillomavirus (HPV) vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

The treatment landscape for advanced HR-positive / HER2-negative breast cancer is continually evolving. CDK4/6 inhibitors, such as Pfizer’s Ibrance and Novartis’s Kisqali, are commonly used in…

TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, howeverbut competing biologics such as IL-17 inhibitors (Cosentyx, Taltz, Bimzelx), IL…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…

Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. 2023 saw the…

Clarivate Epidemiology’s coverage of Hemophilia A comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence of Hemophilia…